Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
Background The dismal clinical outcome of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) highlights the need for innovative targeted therapies. Although chimeric antigen receptor (CAR)-engineered T cells have revolutionized the treatment of B cell malignancies, their clinical...
Saved in:
| Main Authors: | Pablo Menendez, Diego Sánchez Martínez, Néstor Tirado, Alba Martínez-Moreno, Anaïs Jiménez-Reinoso, Víctor M Díaz, Marina García-Peydró, Oana Hangiu, Laura Díez-Alonso, Ángela Albitre, Petronila Penela, Maria L Toribio, Luis Álvarez-Vallina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/12/e005333.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia
by: Néstor Tirado, et al.
Published: (2025-07-01) -
Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
by: Andrew D. Hughes, et al.
Published: (2025-01-01) -
Primary B-cell lymphoblastic lymphoma of the ovary
by: Anjana Joel, et al.
Published: (2018-01-01) -
Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia
by: Chelsea Vrana, et al.
Published: (2025-01-01) -
Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia.
by: Chelsea Vrana, et al.
Published: (2025-01-01)